Clareo Health | Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
With
University Hospital of Crete
To evaluate whether the administration of consolidation therapy with docetaxel/carboplatin after induction chemotherapy followed by concurrent chemoradiotherapy, offers any advantage regarding time to tumor progression
Age
19–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically or cytologically confirmed, unresectable locally advanced (stage IIIA/IIIB) NSCLC
no previous therapy for NSCLC is allowed
age \>18 years
bidimensionally measurable disease
performance status (WHO) 0-2
absence of pleural effusion
adequate liver (serum bilirubin \< 1.5 times the upper normal limit (UNL); AST and ALT \< 2.5 times the UNL in the absence of demonstrable liver metastases, or \< 5 times the UNL in the presence of liver metastases); adequate renal function (serum creatinine \< 1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function
life expectancy of more than 3 months
written informed consent
You may not be if
active infection
history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)
malnutrition (loss of ≥ 20% of the original body weight)
performance status: 3-4
sensor or motor neuropathy \> grade I
second primary malignancy, except for non-melanoma skin cancer
psychiatric illness or social situation that would preclude study compliance
